Clinical

Epcoritamab added to R2 sharply boosts follicular lymphoma responses, but infection risks and real-world feasibility raise tough treatment decisions.

Nirmatrelvir-ritonavir was most likely to be cost-effective among adults aged 18 to 64 years with comorbidities, particularly those with lung disease or immune disorders.

Real-world data show zanubrutinib cuts atrial fibrillation, major bleeding, and mortality versus ibrutinib in B‑cell cancers—guiding safer BTK inhibitor choices.

Their study found cost nudges had minimal effect on clinic selection, as 85% already chose lower-cost tiers, suggesting tiered benefit design works.

Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.

Patients with late-onset multiple sclerosis are less likely to receive high-efficacy disease-modifying therapies than younger patients.

BCBSNC Foundation president Colleen Briggs, MBA, outlines youth mental health, health through food, and care access priorities, then reflects on the next 25 years.

The POSITIVE study's 2-year real-world data confirm that tildrakizumab drives near-total skin clearance and sustained improvement in difficult-to-treat areas, lending important practical validity to the phase 3 trial results.

Panretinal laser photocoagulation was found to be inferior when compared with brolucizumab in patients with proliferative diabetic retinopathy.

Muhammad Bilal Abid, MD, discusses COVID prevention gaps, monoclonal antibodies, and infection risk in immunocompromised patients with CLL.

Katie Eyes, MSW, reflects on 25 years of the BCBSNC Foundation and, over her 18 years with the organization, its shift toward upstream, systems-level health solutions.

Loss of a partner or sibling during the pandemic was associated with heightened cardiovascular vulnerability, according to one study.

Bepirovirsen data show the potential for a functional cure for chronic hepatitis B by lowering HBsAg and boosting immune control.

As president of the BCBSNC Foundation, Colleen Briggs, MBA, reflects on 25 years of progress and outlines where the organization is headed next.

Carolina Barnett-Tapia, MD, PhD, discusses the results of the ADAPT OCULUS trial, which found promising results for treating patients with ocular myasthenia gravis.

These indications cover HIV, type 1 diabetes, chronic hives, genetic-related hearing loss, and lupus.

Ez-PAVE delivers the first direct trial evidence that targeting LDL below 55 mg/dL is superior to below 70 mg/dL in ASCVD patients—providing proof of concept for treat-to-target strategies and a wake-up call about clinical inertia.

Systemic therapy for CSCC is evolving toward earlier use, combination and de-escalation strategies, and biomarker-driven personalization to improve outcomes and reduce toxicity.

Long-acting therapies could be key to engaging unsuppressed patients and closing persistent gaps in HIV care.

Landmark analyses from VESALIUS-CV reveal that the cardiovascular benefits of intensive LDL lowering build meaningfully over time in primary prevention—reinforcing the "lower for longer" principle and pointing toward lower LDL targets for high-risk diabetic patients.

Fatima Cody Stanford, MD, MPH, MPA, exposes obesity health disparities, GLP-1 access hurdles, payer policy fixes, and how stigma in care blocks equitable treatment.

Panelists examine the societal impact of stroke by outlining its prevalence, underlying pathophysiology, key modifiable risk factors, and the substantial clinical, economic, and long-term disability burden it places on patients and the healthcare system.

Panelists explore stroke classification and clinical presentation, highlighting key differences between ischemic and hemorrhagic strokes, the TOAST system for subtype identification, and the importance of understanding underlying causes to guide diagnosis and long-term management.

Poor housing affordability and quality raised risks of frailty, disability, and death in older adults, yet neighborhood quality showed no independent association.

New data show how systemic inflammation independently raises the risk of CKD progression and cardiovascular events after acute myocardial infarction.